Friday, 16 October 2026European Markets

UMICORE And VOW Have A High Dividend Yield And Return On Equity In The Pollution & Treatment Controls Industry.

Loading stream...

(VIANEWS) - UMICORE (UMI.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Pollution & Treatment Controls industry.

Financial Asset Price Forward Dividend Yield Return on Equity
UMICORE (UMI.BR) €23.82 3.41% 13.58%
VOW (VOW.OL) kr10.30 0.45% 1.13%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. UMICORE (UMI.BR)

3.41% Forward Dividend Yield and 13.58% Return On Equity

Umicore SA operates as a materials technology and recycling company worldwide. It operates through Catalysis, Energy & Surface Technologies, and Recycling segments. The Catalysis segment produces automotive catalysts for gasoline, and diesel light and heavy-duty diesel applications; stationary catalysis for industrial emissions control; and precious metals-based compounds and catalysts for use in the pharmaceutical and fine chemicals industries, as well as fuel cell applications. The Energy & Surface Technologies segment offers cobalt and specialty materials, rechargeable battery materials, and electro-optic materials, as well as metal deposition solutions, including electroplating and PVD coating. The Recycling segment treats waste streams containing precious and other specialty metals from a range of industrial residues and end-of-life materials. This segment also produces precious metals-based materials for glass production, electric, and electronic applications. The company was formerly known as Union Minière du Haut Katanga and changed its name to Umicore SA in 2001. Umicore SA was founded in 1805 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, UMICORE has a trailing twelve months EPS of €2.02.

PE Ratio

UMICORE has a trailing twelve months price to earnings ratio of 11.79. Meaning, the purchaser of the share is investing €11.79 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.58%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, UMICORE's stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 22.3%, now sitting on 22.57B for the twelve trailing months.

More news about UMICORE.

2. VOW (VOW.OL)

0.45% Forward Dividend Yield and 1.13% Return On Equity

Vow ASA, together with its subsidiaries, produces, delivers, and maintains systems for processing and purifying wastewater, food waste, solid waste, and bio sludge in Norway, France, Poland, the United States, and Italy. It operates in three segments: Projects Cruise, Aftersales, and Landbased. The Projects Cruise segment delivers ship systems to shipyards for newbuild constructions, which include advanced wastewater purification, waste management, and food waste processing; and advanced systems to shipowners for ships. The Aftersales segment provides spare parts and consumables; chemicals; and tailor-made service and maintenance programs. The Landbased segment offers Biogreen, a patented pyrolysis process for converting biomass, plastics, and waste into energy; Safesteril, a patented sterilisation process for food and pharmaceutical ingredients; and industrial robotics solutions, including robotic systems for waste recycling processes. This segment also develops, designs, and fabricates industrial furnaces and equipment for heat treatment processes. The company serves cruise, aquaculture, and landbased industries, as well as utilities. It has a strategic partnership agreement with Repsol, S.A. to explore applications and solutions to produce clean and renewable energy for CO2 emission reduction; European Tyre Enterprise Ltd. to develop a modularised and industrial solutions, and value chain to turn end-of-life tires into raw material and renewable energy; GRTgaz to produce a demo plant built to confirm that CO2 neutral pyrolysis gas can replace fossil gas in the European gas grid; SAS IMPROVE to develop technological solutions for the farm to fork valorisation of future proteins; and Imtech Steri's Biosteam to offer a range of ingredient sterilisation solutions and services. The company was formerly known as Scanship Holding ASA and changed its name to VOW ASA in January 2020. Vow ASA was founded in 2011 and is headquartered in Lysaker, Norway.

Earnings Per Share

As for profitability, VOW has a trailing twelve months EPS of kr0.05.

PE Ratio

VOW has a trailing twelve months price to earnings ratio of 206. Meaning, the purchaser of the share is investing kr206 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.13%.

Volume

Today's last reported volume for VOW is 48593 which is 68.49% below its average volume of 154243.

Moving Average

VOW's value is way under its 50-day moving average of kr13.90 and way under its 200-day moving average of kr14.88.

More news about VOW.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com